Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Cost-Effectiveness Comparison between Ibrutinib, Chemotherapy, and Chemoimmunotherapy in Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Chadi Nabhan, MD, Damion Nero, PhD, Choo Hyung Lee, MA, MS, Jonathan K. Kish, PhD MPH, Anthony R. Mato, MD MSCE

Blood (2018) 132 (Supplement 1): 4757.

https://doi.org/10.1182/blood-2018-99-118640

Published: 2018

Journal Articles

Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax (VEN) or Chemotherapy (CT)/Chemoimmunotherapy (CIT)

Chadi Nabhan, MD, Anthony R. Mato, MD MSCE, Jonathan K. Kish, PhD MPH, Damion Nero, PhD

Blood (2018) 132 (Supplement 1): 4758.

https://doi.org/10.1182/blood-2018-99-118904

Published: 2018

Journal Articles

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Jessica Chung, PhD MPH, Damion Nero, PhD, Bruce Feinberg, DO, Jonathan Kish, PhD MPH, Chadi Nabhan, MD MBA, FACP

Blood (2017) 130 (Supplement 1): 3449.

https://doi.org/10.1182/blood.V130.Suppl_1.3449.3449

Published: 2017

Journal Articles

Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy

Chadi Nabhan, MD MBA, FACP, Jessica Chung, PhD MPH, Anthony R. Mato, MD, Jonathan Kish, PhD MPH, Damion Nero, PhD

Blood (2017) 130 (Supplement 1): 2111.

https://doi.org/10.1182/blood.V130.Suppl_1.2111.2111

Published: 2017

Journal Articles

Comparative Study of Cardiovascular Co-Morbidities between Ibrutinib and Non-Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) Patients

Damion Nero, PhD, Jessica Chung, PhD MPH, Anthony R. Mato, MD, Jonathan Kish, PhD MPH, Chadi Nabhan, MD MBA, FACP

Blood (2017) 130 (Supplement 1): 4692.

https://doi.org/10.1182/blood.V130.Suppl_1.4692.4692

Published: 2017

NARROW

Cost-Effectiveness Comparison between Ibrutinib, Chemotherapy, and Chemoimmunotherapy in Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax (VEN) or Chemotherapy (CT)/Chemoimmunotherapy (CIT)

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy

Comparative Study of Cardiovascular Co-Morbidities between Ibrutinib and Non-Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) Patients

Email alerts

ASH Publications

American Society of Hematology

Cost-Effectiveness Comparison between Ibrutinib, Chemotherapy, and Chemoimmunotherapy in Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)

Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax (VEN) or Chemotherapy (CT)/Chemoimmunotherapy (CIT)

The Impact of Depression and Use of Anti-Depressants on Healthcare Resource Utilization (HCRU) in Multiple Myeloma (MM) Patients

Comparison of Costs and Health Care Resource Utilization (HRU) in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Front-Line Ibrutinib or Chemoimmunotherapy

Comparative Study of Cardiovascular Co-Morbidities between Ibrutinib and Non-Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL) Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only